Dornase alfa is contraindicated in patients who have had hypersensitivity reactions from using any products containing Chinese hamster ovary cell products or ingredients.

Using the drug during pregnancy and breastfeeding requires the prescribing clinician to weigh the risks vs. benefits of such therapy, although there is no risk of teratogenicity, and there is also no expected harm to infants based on the drug's mechanism of action. It is unknown whether the dornase alfa affects milk production.

Dornase alfa has no known clinically relevant drug interactions.